How Bradway was paid
$24.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Robert A. BradwayChief Executive Officer and President | $1,925,409 | — | $12,599,589 | $5,399,996 | $3,907,000 | $861,126 | $24,693,120 |
| Peter H. GriffithExecutive Vice President and Chief Financial Officer | $1,223,994 | — | $3,709,745 | $1,589,962 | $1,652,000 | $435,186 | $8,610,887 |
| Murdo GordonExecutive Vice President, Global Commercial Operations | $1,233,189 | — | $3,709,745 | $1,589,962 | $1,668,000 | $322,575 | $8,523,471 |
| David M. ReeseExecutive Vice President and Chief Technology Officer | $1,306,721 | — | $3,359,787 | $1,439,965 | $1,768,000 | $415,835 | $8,290,308 |
| James E. BradnerExecutive Vice President, Research and Development | $1,238,580 | $500,000 | $3,359,787 | $1,439,965 | $1,675,000 | $426,535 | $8,639,867 |
What changed and why
- 10%Total revenues and sales grew 10% year-over-year with record sales for 18 products in 2025.
- $24.7MCEO Robert A. Bradway total compensation increased to $24,693,120 in 2025.
- The company received five important FDA regulatory approvals and advanced the MariTide Phase 3 program.
- 94%Stockholders expressed strong support with a 94% approval vote on say-on-pay in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.